Wealthfront’s Sarepta Therapeutics SRPT Stock Holding History

Wealthfront’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-127	Closed	-$4K	–	1420
2015 Q2	$4K	Buy	+127	New	+$2.6K	﹤0.01%	1104

Other funds holding SRPT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wealthfront's SRPT Position: Q3 2015 in Review

Wealthfront sold out of Sarepta Therapeutics (SRPT) in Q3 2015, closing a stake of 127 shares — an estimated $4K sold.

Wealthfront first reported a position in SRPT in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 149 funds tracked by Wall St. Rank hold SRPT as of Q3 2015.

Wealthfront reported no remaining Sarepta Therapeutics position as of Q3 2015 after selling out during the quarter.
Wealthfront sold 127 Sarepta Therapeutics shares in Q3 2015, an estimated $4K.
Wealthfront first reported a position in Sarepta Therapeutics in Q2 2015 and held it in 1 quarter.
Wealthfront's Sarepta Therapeutics position peaked at $4K in Q2 2015.
149 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2015.

Based on Wealthfront's 13F filing for Q3 2015, filed 18 Nov 2015.